focus -WSS

focus

author：focus 2025-09-28 23:44:46 - browse：88

Photo illustration of Covid 19 testing swabs on a blue background. — Timothy Stenzel led the FDA's diagnostics division during the Covid-19 pandemic, as the agency scrambled to push through and validate accurate Covid tests. Adobe

Timothy Stenzel, the federal regulator who led the Food and Drug Administration’s diagnostics division during the chaotic time of Covid-19 pandemic, has left the agency. The FDA confirmed Thursday that Stenzel, who led the FDA’s office of in vitro diagnostics, retired at the end of 2023.

During the early days of the pandemic, Stenzel was in the middle of a turf battle between the Centers for Disease Control and Prevention and the FDA over the regulation of Covid tests. At one point, the CDC made Stenzel wait at its facility overnight after he arrived for a meeting on Covid test development, Politico reported at the time.

It was a hectic time. Testmakers rapidly introduced new Covid-19 screening products with little data, as it was a brand new virus. The pandemic especially laid bare FDA’s inability to control lab-developed tests (LDTs). Many of the Covid-19 PCR tests fell in this category. Early on, using powers granted by the public health emergency, the FDA required labs to apply for emergency use authorization. But a STAT investigation found that the Department of Health and Human Services told the FDA to stop this measure, despite knowing that many of the tests may have been inaccurate.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Supreme Court strikes down use of affirmative action
Next article： Midwives could help bridge maternal health disparities in the U.S.

WSS

STAT Health News: mRNA flu shots, Purdue SCOTUS case, etc

Neurocrine congenital adrenal hyperplasia trial succeeds

STAT Health News: mRNA flu shots, Purdue SCOTUS case, etc

STAT Event – Decoding Clinical Trials: Venture Capitalists Talk Early Biotech R&D

Pregnancy discrimination could be enabled by AI

AI models in health care face new federal disclosure requirements

leisure time

focus

focus

Moonlake's readout produced a cash windfall. Risks remain

AbbVie buys Immunogen, maker of targeted cancer drugs, for $10B

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

FDA approves world's first CRISPR

Bright Health sells Medicare Advantage business to Molina

Chemotherapy shortages won’t get better under Biden’s latest plan

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

White House Covid adviser calls on docs to combat misinformation

Anesthesiologist group: stop taking Ozempic before surgery

Radiology is caught between AI's potential and concern for patients

leisure time

Americans' trust in science, scientist continues decline: Report

Neurocrine congenital adrenal hyperplasia trial succeeds

Fed up with FDA, ALS advocates consider a take

FDA panel to weigh safety of artificial wombs for preterm births

Why sickle cell disease is getting the first CRISPR treatment

Pfizer plans to depart BIO

focus

knowledge

hotspot

entertainment